

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/981,506	10/17/2001	Gregory R. Chiklis	19383-014	6911
35437	7590 03/24/2003			
MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO			EXAMINER	
666 THIRD A NEW YORK			PARK, HANKYEL 4	
			ART UNIT	PAPER NUMBER
			1648	
			DATE MAILED: 03/24/2003	•

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)				
_		09/981,506	CHIKLIS ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Hankyel T. Park	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
	Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status	December to communication (a) find an 47.0	N-4-1 0004					
1)⊠	Responsive to communication(s) filed on <u>17 C</u>						
2a)☐	,—	s action is non-final.	on a suiting on to the granuite in				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) Claim(s) 1-69 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5)⊠ Claim(s) <u>34-69</u> is/are allowed.							
·	6)⊠ Claim(s) <u>1-33</u> is/are rejected.						
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement. Application Papers							
9)☐ The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>3</u> .	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/981,506 Page 2

Art Unit: 1648

DETAILED ACTION

1. Claims 1-69 are pending.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 3. Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent 5,777,095. The patent discloses a non-pathogenic microorganism used for live vaccines. The non-pathogenicity was obtained by alteration or modification by mutagenization, chemical, enzymatic or heat treatment, or by another equivalent treatment resulting in an modification of the outer surface protein. (See column 19, lines 48-63). The nuclear components are presumed to be intact.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 09/981,506 Page 3

Art Unit: 1648

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 1-33 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent 5,777,095 ('095).

Claims 1-33 of the instant application are directed to microorganism comprising surface proteins and substantially intact nuclear components, wherein one or more surface proteins have been irreversibly modified such that the microorganism is thereby rendered non-pathogenic. The limitations to the broad claim are various compounds or enzymes that react to the surface proteins or various microorganisms.

The '095 patent discloses microorganism used for live vaccines in a broad sense. This is supported by the statement that mentions a non-pathogenic *E. Coli* as being one example of microorganism (column 19, lines 49-50). The '095 patent also lists modification method, which includes chemical and enzymatic treatment (column 19, lines 57-59).

Application/Control Number: 09/981,506 Page 4

Art Unit: 1648

It would have been prima facie obvious for one of ordinary skill in the art at the time the invention was made to obtain microorganisms of the instant application because the one of ordinary skill would be motivated to use various chemical compounds and enzymatic treatments and various microorganisms to obtain live vaccines that are non-pathogenic as taught by '095 patent, lacking any evidence to the contrary.

Applicants' invention regarding amplification of nuclear components of the microorganism is, however, deemed to distinguish over the prior art.

- 6. Claims 1-33 are not allowed.
- 7. Papers relating to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 located in Crystal Mall 1. The Fax number for Art Unit 1648 is (703) 308-4242. All Group 1600 Fax machines will be available to receive transmissions 24 hrs/day, 7 days/wk. Please note that the faxing of such papers must conform with the Notice published in the Official Gazette, 1096 OG 30, (November 15, 1989).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Hankyel T. Park, Ph.D., whose telephone number is (703) 305-7255. The Examiner can normally be reached on Monday, Tuesday, Thursday and Friday from 6:30 AM-4:00 PM, (EST). The Examiner can also be reached on alternate Wednesdays.

Application/Control Number: 09/981,506

Page 5

Art Unit: 1648

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, James C. Housel, can be reached at (703) 308-4027.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

March 21, 2003

HANKYEL T. PARK, PH.D PRIMARY EXAM!NER